Both the MGMT promoter methylation status and the radiomics signature stratified the glioma patients into a high-risk group and a low-risk group (p = 0.0002 and 0.04, respectively), and the differences within the high- and low-risk groups did not reach statistical significance. This evidence concerns the gene MGMT and glioma.